HCV & Substance Misuse

Hep C: Issues in PWID

Activity Details
  • Credit Amounts:
    • CME: 0.50
    • Other: 0.50
    • CPHCE: 1.00
  • Cost: Free
  • Release: Sep 5, 2019
  • Expires: Sep 4, 2022
  • Estimated Time to Complete:
    30 Minutes
  • Average User Rating:
    (6 Ratings)


Melissa K.  Osborn Jenkins Melissa K. Osborn Jenkins, MD, MS
Associate Professor, Medicine
Case Western Reserve University School of Medicine
Staff Physician, Infectious Diseases
MetroHealth Medical Center
Cleveland, Ohio

Needs Statement

Hepatitis C treatment is often withheld from PWID due to concerns regarding adherence, perceived lack of efficacy, and perceived risk of reinfection. PWID are a difficult to reach population leading to lower rates of linkage to care. Failure to address HCV in PWID will lead to failure to eradicate HCV.

This activity has been approved by the KBML as meeting the statutory requirements of HB1.

Target Audience

Health care providers offering treatment to PWID


Upon completion of this education activity, participants will be able to:

  • Discuss hepatitis C treatment-related issues in PWID (people who inject drugs) and people on OST (opioid substitution therapy) including response rates and adherence
  • Describe novel approaches to treatment to improve linkage-to-care and completion of therapy in this population
  • Relate the importance of targeting PWID in relation to public health and elimination of hepatitis C


The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0418-H3.5-UK19a

ACGME Competencies

  • Patient care
  • Medical knowledge

UK Healthcare CECentral certifies this activity for 0.50 hours of participation.

University of Kentucky College of Public Health certifies that this educational activity was designated for 1.00 hour of Public Health Continuing Education (CPHCE) credit. This course is approved for continuing education by the University of Kentucky College of Public Health. ()

Faculty Disclosure

Dr. Osborn Jenkins (speaker) has relevant financial relationships with commercial interests as follows:

  • Gilead Sciences - Investigator - Salary support for research (FOCUS Project)

No planners have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speaker. In some cases, the presentation might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. The speaker will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


In collaboration with Kentucky Injury Prevention and Research Center (KIPRC).